Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending

The Phase 3 readout is the first for ivonescimab beyond non-small cell lung cancer to show a significant overall survival benefit, according to Summit Therapeutics and China-based partner Akeso.